Boron neutron capture therapy of brain tumors: Past history, current status, and future potential

Cancer Investigation

Volumn 14, Issue 6, 1996, Pages 534-550

  Barth, Rolf F ^a   Soloway, Albert H ^a   Brugger, Robert M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BORONOPHENYLALANINE; BOROCAPTATE; BORON DERIVATIVE; UNCLASSIFIED DRUG;

BRAIN TUMOR; HUMAN; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0030458431     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609076899     Document Type: Review

References (144)

1. Soloway AH, Barth RF, Carpenter DE, eds: Advances in Neutron Capture Therapy. New York, Plenum Press, 1994.
2. Gabel D, Moss R, eds: Boron Neutron Capture Therapy. New York, Plenum Press, 1992.
3. Mishima Y, ed: Cancer Neutron Capture Therapy. New York, Plenum Press, 1996.
4. Barth RF, Soloway AH, Fairchild RG, Brugger RM: Boron neutron capture therapy for cancer: Realities and prospects. Cancer 70:2995-3007, 1992.
5. Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl 32:950-984, 1994.
6. Dorn RV: Boron neutron capture therapy (BNCT): A radiation oncology perspective. Int J Radiat Oncol Biol Phys 28:1189-1201, 1994.
7. Hatanaka H, Kamano S, Amano K, et al: Clinical experience of boron-neutron capture therapy for gliomas:a comparison with conventional chemo-immuno-radio-therapy. In: Boron Neutron Capture Therapy for Tumors, edited by H Hatanaka. Niigata, Japan: Nishimura Co., 1986, pp 349-378.
8. Hatanaka H: Boron neutron capture therapy for tumors. In: Glioma, edited by ABMF Karim, E Laws. New York. Springer Verlag, 1991, pp 233-249.
9. Hatanaka H, Nakagawa Y: Clinical results of long-surviving brain tumor patients who underwent boron capture therapy. Int J Radiat Oncol Biol Phys 28:1061-1066, 1994.
10. 10B-compound Lancet 2:388-389, 1989.
11. 10B molecule-melanoma cell interaction from in vitro to first clinical trial. Pigment Cell Res 2:226-234, 1989.
12. Mishima Y, Honda C, Ichihashi M, et al: Selective melanoma thermal neutron capture therapy for lymph node metastases. In: Advances in Neutron Capture Therapy, edited by AH Soloway, RF Barth, DE Carpenter. New York, Plenum Press, 1993, pp 705-710.
13. 7Li reaction in HeLa cells. Radiat Res 43:534-553, 1970.
14. Javid M, Brownell GL, Sweet WH: The possible use of neutron-capture isotopes such as boron-10 in the treatment of neoplasms. II. Computation of the radiation energy and estimates of effects in normal and neoplastic brain. J Clin Invest 31:603-610, 1952.
15. Tolpin El, Wellum G.R. Dohan FC Jr, et al: Boron neutron capture therapy of cerebral gliomas. II. Utilization of the blood-brain barrier and tumor-specific antigens for the selective concentration of boron in gliomas. Oncology (Basel) 32:223-246, 1975.
16. Barth RF, Alam F, Soloway AH, et al: Delivery of boron-10 for neutron capture therapy by means of polyclonal and monoclonal antibodies: Progress and problems. In: Neutron Capture Therapy, edited by H. Hatanaka. Niigata, Japan, Nishimura, 1986, pp 8-16.
17. Gupta N, Gahbauer RA, Blue TE, Wambersie A: Dose prescription in boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28:1157-1166, 1994.
18. 103-neutron capture therapy for early skin reaction in the hamster. Radiat Res 128:186-191, 1991.
19. 7Li reaction on cultured B-16 melanoma cells. Int J Radiat Biol 1:167-175, 1987.
20. Gahbauer RA, Fairchild RG, Goodman JH, Blue TE: RBE in normal tissue studies. Boron. In: Neutron Capture Therapy, edited by D. Gabel, R. Moss. New York, Plenum Press, 1992, pp 123-128.
21. Solares GR, Guillermo C, Palano J, Zamenhof: High resolution quantitative autoradiography and its application to microdosimetry of boron neutron capture therapy. In: Topics in Dosimetry and Treatment Planning for Neutron Capture Therapy, edited by RG Zamenhof, GR Solares, OK Harling. Madison, WI, Advanced Medical Publishing, 1994, pp 13-27.
22. Ausserer WA, Ling Y-C, Chandra S, Morrison GH: Quantitative imaging of boron, calcium, magnesium, potassium, and sodium distributions in cultured cells with ion microscopy. Anal Chem 61:2690-2695, 1989.
23. Bendayan M, Barth RF, Gingras D et al: Electron spectroscopic imaging for high resolution immunocytochemistry: Use of boronated protein A. J Histochem Cytochem 37:573-580, 1989.
24. Kobayashi T, Kanda K: Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat Res 91:77-94, 1982.
25. 7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat Res 111:14-25, 1987.
26. Charlton DE: Energy deposition in small ellipsoidal volumes by high-LET particles: Application to thermal neutron dosimetry. Int J Radiat Biol 59:827-42, 1991.
27. Wuu CS, Amols HI, Kliauga P: Microdosimetry for boron neutron capture therapy. Radiat Res 130:355-9, 1992.
28. 10B(n,α)Li reaction occurring al the cellular membrane. Int J Radiat Oncol Biol Phys 31:171-178, 1995.
29. Utsumi H, Ichihashi M, Kobayashi T, Elkind MR: Sublethal and potentially lethal damage repair on thermal neutron capture therapy. Pigment Cell Res 2:337-42, 1989.
30. Rofstad E: Radiation biology of malignant melanoma. Acta Radiol 15:1-10, 1986.
31. Leibel SA, Sheline GE: Radiation therapy for neoplasms of the brain. J Neurosurg 66:1-22, 1987.
32. Hatanaka H, Masuzawa T, Amano K, et al: Basic and clinical studies on boron-neutron capture therapy. Nippon Acta Neuropathol 9:37-40, 1968.
33. Barth RF: Biologic considerations in targeting brain tumors for boron neutron capture therapy. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp 533-540.
34. Gavin PR, Wheeler FJ, Huiskamp R, et al: Large animal normal tissue tolerance using an epithermal neutron beam and borocaptate sodium. Strahlenther Onkol 169:48-51, 1993.
35. Gabel D: Radiobiological considerations concerning the develop-ment of compounds for boron neutron capture therapy. Strahlenther Oncol 169:65-70, 1993.
36. Allen BJ: Maximum therapeutic depth in thermal neutron capture therapy. Strahlenther Onkol 169:34-41, 1993.
37. Mirkovic N, Meyn RE, Hunter NR, Milas L: Radiation-induced apoptosis in a murine lymphoma in vivo. Radiother Oncol 33:11-16, 1994.
38. Farr LE, Sweet WH, Robertson, JS, et al: Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol 71:279-293, 1954.
39. Asbury AK, Ojemann RG, Nielson SL, Sweet WH: Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31:278-303, 1972.
40. Spielvogel BF: Choose a new path: boron biologicals. In: Biotechnology in the Feed Industry, edited by TD Lyons, KA Jacques. Nottingham, UK, Nottingham University Press, 1994, pp 303-321.
41. Coderre JA, Bergland R, Chadha M, et al. Boron neutron capture therapy of glioblastoma multiforme using p-boronophenylalaninefructose complex and epithermal neutrons. In: Cancer Neutron Capture Therapy, edited by Y. Mishima. New York, Plenum Press, 1996, pp 553-562.
42. Snyder HR, Reedy AJ, Lennary WJ : Synthesis of aromatic boronic acids: Aldehyde boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc 80:835-838, 1958.
43. Belkhou R, Abbé J Ch, Pham P, et al: Uptake and metabolism of boronophenylalanine in human uveal melanoma cells in culture. Relevance to boron neutron capture therapy of cancer cells. Amino Acids 8:217-229, 1995.
44. Zakharkin LI, Grefennikov AV, Luvov AI: Synthesis of some nitrogenous boron derivatives. Izv Akad Nauk SSSR Ser Khim 1:106-112, 1970.
45. Petterson O-A, Olsson D, Lindström P, et al: Penetration and binding L- and D-carboranylalanine in human melanoma spheroids. Melanoma Res 3:369-376, 1993.
46. Yong JH, Barth RF, Wyzlic IM, et al: In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy. Anticancer Res 15:2039-2044, 1995.
47. Fauchere JL, Do KQ, Jow PYC, Hansch C: Universally strong lipophilicity of "fat" or "super" amino acids, including a new reference value for glycine. Experientia 36:1203-1204, 1980.
48. Wyzlic IM, Beeson JC, Soloway AH, et al: New unnatural boron-containing amino acids and peptides as potential delivery agents for neutron capture therapy. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1966 (in press).
49. Schinazi RF, Prusoff WH: Synthesis of 5-(dihydroxyboryl)-2′-deoxyuridine and related boron-containing pyrimidines. J Org Chem 50:841-847, 1985.
50. Yamamoto Y, Seko T, Nakamura H, Nemoto H: Synthesis of carborane-containing nucleoside bases. Heteroatom Chem 3:239-244, 1992.
51. Tjarks W, Anisuzzaman AKM, Liu L, et al: Synthesis and in vitro evaluation of boronated uridine and glucose derivates for neutron capture therapy. J Med Chem 35:1628-1633, 1992.
52. Rong FG, Soloway AH, Ikeda S, Ives DH: Synthesis and biochemical activity of 5-tethered carborane-containing pyrimidine nucleosides as potential agents for DNA incorporation. Nucleosides Nucleotides 14:1873-1887, 1995.
53. Kahl SB, Koo MS: Synthesis of tetrakis-carborane-carboxylate esters of 2,4-bis-(α,β-dihydroxyethyl)-deuteroporphyrin IX. J Chem Soc Chem Commun 24:1769-1771, 1990.
54. Lemmen P, Werner B, Streicher B: Ether lipids as potential boron carriers for boron neutron capture therapy: Synthesis of rac-1-(9-0-carboranyl) nonyl-2-methyl-glycero-3-phosphocholine (B-Et-11-OMe). In: Advances in Neutron Capture Therapy, edited by AH Soloway, RF Barth, DE Carpenter. New York, Plenum Press, 1993, pp 297-300.
55. Scobie M, Threadgill MD: Synthesis of carbonne- containing nitroimidazole compounds via mild 1,3-dipolar cycloaddition. J Chem Soc Chem Commun 13:939-941, 1992.
56. Fairchild RG, Kahl SB, Laster BH, et al: In vitro determination of uptake, retention, distribution, biological efficacy and toxicity of boronated compounds for neutron capture therapy: A comparison of porphyrins and sulfhydryl boron hydrides. Cancer Res 51:4860-4865, 1990.
57. Kahl SB, Joel DD, Nawrocky MM, et al: Uptake of a certain nidocarboranyl porphyrins by human glioma xenografts in athymic nude mice and by syngeneic ovarian carcinomas in immunocompetent mice. Proc Natl Acad Sci USA 87:7265-7269, 1990.
58. Hill JS, Kahl SB, Kaye AH, et al: Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc Natl Acad Sci USA 89:1785-1789, 1992.
59. Laster BH, Kahl SB, Warkentien L, Bond VP: In vivo studies in NCT with a boronated porphyrin and tumor growth delay as end point. In: Advances in Neutron Capture Therapy, edited by AH Soloway, RF Barth, DE Carpenter. New York, Plenum Press, 1993, pp 535-539.
60. Holley JL, Mather A, Wheelhouse RT, et al: Targeting of tumor cells and DNA by a chlorambucil-spermidine conjugate. Cancer Res 52:4190-4195, 1992.
61. 8-aziridinyl analogues of spermidine. Cancer Res 54:742-748, 1994.
62. Marton LJ, Pegg AE: Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 35:55-91, 1995.
63. Hariharan JR, Wyzlic IM, Soloway AH: Synthesis of novel boroncontaining polyamines - Agents for DNA targeting in neutron capture therapy. Polyhedron 14:823-825, 1995.
64. Hawthorne MF, Wiersema RJ, Takasugi M: Preparation of tumorspecific boron compounds. 1. In vitro studies using boron-labeled antibodies and elemental boron as neutron targets. J Med Chem 15:449-453, 1972.
65. Barth RF, Johnson CW, Wei W-Z, et al: Neutron capture using boronated monoclonal antibody directed against tumor-associated antigens. Cancer Detect Prev 5:315-323, 1982.
66. Alam F, Soloway AH, Barth RF: Boronation of antibodies with mercaptoundecahydro-closo-dodecaboratc (2-) anion for potential use in boron neutron capture therapy. Int J Radiat Appl Instrum Part A 38:503-506, 1987.
67. Barth RF, Alam F, Soloway AH, Adams DM, Steplewski Z: Boronated monocloncal antibody 17-1A for potential neutron capture therapy of colorectal cancer. Hybridoma 5:S43-S50, 1986.
68. Barth RF, Adams DM, Soloway AH, et al: Boronated starburst dendrimer-monoclonal antibody as a potential delivery system for neutron capture therapy. Bioconjugate Chem 5:58-66, 1994.
69. Liu L, Barth RF, Adams DM, Soloway AH, Reisfeld RA: Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J Hematother 4:477-483, 1995.
70. Pak RH, Primus FJ, Rickard-Dickson KJ, et al: Preparation and properties of nido-carborane-specific monoclonal antibodies for potential use in boron neutron captures therapy for cancer. Proc Natl Acad Sci USA 92:6986-6990, 1995.
71. Libermann TA, Razon N, Bartal AD, et al: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44:753-760, 1984.
72. Wong AJ, Bigner SH, Bigner DD, et al: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899-6903, 1987.
73. Epenetos A, Courtenay-Luck N, Pickering D, et al: Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J 280:1463-1466, 1985.
74. Herlyn D, Bender H, Adachi K, et al: Monoclonal antibody targeting of epidermal growth factor receptor on human malignant gliomas. In: Monoclonal Antibodies and Applications, edited by A Epenetos. London, Chapman and Hall Medical, 1993, pp 219-226.
75. Kalofonos HP, Pawlikowska TR, Hemingway A, et al: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antiodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636-45, 1989.
76. 131I conjugates on the clonogenic survival of cultured glioma cells. J Neuro-oncol 14:213-223, 1992.
77. 125I-labeled epidermal growth factor-dextran conjugates in mice. In: Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science. Uppsala, Sweden, Acta Univ Upsaliensis, 1993, p. 428.
78. Carlsson J, Gedda L, Grönvik C, et al: Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys 30(1): 105-115, 1994.
79. Capala J, Barth RF, Bendayan M, et al: Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjugate Chem 7-15, 1996.
80. Smith MD, Setiawan Y, Moore DE: Optimisation of drug anchor for ortho-carborane in reconstitution of low density lipoproteins for neutron capture therapy. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp. 143-150.
81. Shelly K, Feakes DA, Hawthorne MF, et al: Model studies directed toward the boron neutron capture therapy of cancer:boron delivery to murine tumors with liposomes. Proc Natl Acad Sci USA 89:9039-9043, 1992.
82. Feakes DA, Shelly K, Hawthorne M: Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci USA 92:1367-1370, 1995.
83. Richardson RB, Davies AG, Bourne SP: Radioimmunolocalisation of human brain tumours: Biodistribution of radiolabelled monoclonal antibody UJ13A. Eur J Nucl Med 12:313-320, 1986.
84. Agamemnon A, Epenetos A, Snook D, et al: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183-3191, 1986.
85. Lee Y, Bullard DE, Wikstrand CJ, et al. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res 47:1941-1946, 1987.
86. Neuwelt EA, Barnett PA, Hellström I, et al: Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 48:4725-4729, 1988.
87. Yang W, Barth RF, Carpenter DE, et al: Enhanced delivery of boronophenylalanine to brain tumors for neutron capture therapy by means of carotid injection and blood-brain barrier disruption. Neurosurgery 38:985-992, 1996.
88. Yang W, Barth RF, Rotaru J, et al: Enhanced survival of F98 glioma bearing rats following neutron capture therapy with either sodium borocaptate or boronophenylalanine and osmotic blood brain barrier disruption. Anticancer Res 15(5A):1659, 1995.
89. Yang Y, Barth RF, Rotaru JH, et al: Enhanced survival of F98 glioma bearing rats following boron neutron capture therapy with blood brain barrier disruption and intracarotid injection of boronophenylalanine. J Neuro-oncol 1996 (in press).
90. Barth RF, Rotaru J, Staubus AE, et al: Sodium borocaptate and boronophenylalanine alone or in combination as capture agents for BNCT of the F98 rat glioma. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp 553-590.
91. Sweet WH, Soloway AH, Brownell GL: Studies relevant to slow neutron capture therapy of brain tumor. Acta Union Int Cancer 16:1216-1219, 1960.
92. Sweet WH, Soloway AH, Brownell GL: Boron-slow neutron capture therapy of gliomas. Acta Radiol 1:114-121, 1963.
93. Farr LE, Haymaker W, Konikowski T, Lippincott SW: Effects of alpha particles randomly induced in the brain in the neutron-capture treatment of intracranial neoplasms. Int J Neurol 3:564-576, 1962.
94. Farr LE, Robertson JS: Therapy with neutrons. Handb Med Radiol XI, 1961, pp. 1-23.
95. Slatkin DN: A history of boron neutron capture therapy of brain tumors: Brain 114:1609-1629, 1991.
96. Nigg D, ed: Proceedings of the First International Workshop on Accelerator-based Neutron Sources for Boron Neutron Capture Therapy. US Department of Energy Conference Report CONF-940976, 1994.
97. Fairchild RG, Kalef-Ezra JA, Firaman S, et al: Optimization of an epithermal beam for NCT at the Brookhaven Medical Research Reactor (BMRR). Stralenther Onkol 165:84-86, 1989.
98. Brugger RM, Less TD: A progress report. In: Neutron Capture Therapy, edited by H Hatanaka. Niigata, Japan, Nishimura Co., 1986, pp 110-116.
99. Fairchild RF, Kalef-Ezra JA, Saraf SK, et al: Installation and testing of an optimized epithermal neutron beam at the Brookhaven Medical Research Reactor (BMRR). In: Neutron Beam Design, Development and Performance for Neutron Capture Therapy, edited by OK Harling, JA Bernard, RG Zamenhof. New York, Plenum Press, 1990, pp 185-189.
100. Wheeler FJ, Parsons DK, Nigg DW, et al: Physics design for the Brookhaven Medical Research development and performance for NCT. In: Neutron Beam Design, Development and Performance for Neutron Capture Therapy, edited by OK Harling, JA Bernard, RG Zamenhof. New York, Plenum Press, 1990, pp 83-95.
101. Choi JR, Clement SD, Harling OK, et al: Neutron capture therapy beams at the MIT research reactor. In: Neutron Beam Design, Development and Performance for Neutron Capture Therapy, edited by OK Harling, JA Bernard, RG Zamenhof. New York, Plenum Press, 1990, pp 201-218.
102. Clement SD, Choi JR, Zamenhof RG, et al: Monte Carlo methods of neutron design for neutron capture therapy at the MIT research reactor (MITR-II). In: Neutron Beam Design, Development and Performance for Neutron Capture Therapy, edited by OK Harling, JA Bernard, RG Zamenhof. New York, Plenum Press, 1990, pp 51-69.
103. Moss RL: Progress towards boron neutron capture therapy at the high flux reactor Petten. In: Neutron Beam Design, Development and Performance for Neutron Capture Therapy, edited by OK Harling, JA Bernard, RG Zamenhof. New York, Plenum Press, 1990, pp 169-183.
104. Wheeler FJ, Wessol DE, Babcock R: Improvements in patient treatment planning systems. In: Cancer Neutron Capture Therapy, edited by Y Mishima 1996, pp 289-294.
105. Wallace SA, Allen BJ, Mathur JN: Monte Carlo neutron photon treatment planning calculations: modelling from CT scans with variable voxel size. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp 295-302.
106. Wierzbicki JG, Maruyama Y: Treatment planning methods with Cf-252 at the University of Kentucky. Nucl Sci Appl 4:19-27, 1991.
107. Maruyama Y: Clinical radiobiology of Cf-252 for bulky tumor therapy. Nucl Sci Appl 4:29-43, 1991.
108. Laramore GE: Nonreactor sources of epithermal neutron beams for boron neutron capture therapy (BNCT): A user's perspective. In: Proceedings of the First International Workshop on Accelerator-Based Neutron Sources for Boron Neutron Capture Therapy Sept 11-14, 1994, Jackson, WY, edited by D Nigg. US Dept of Energy ConferenceReport CONF-940976, 1994, Vol I, pp 25-33.
109. Liu HB, Brugger RM: Upgrades of the epithermal neutron beam at the Brookhaven medical research reactor. In: Cancer Neutron Capture Therapy, edited by Y Mishima. 1996, pp 343-356.
110. Harling OK, personal communication, 1995.
111. Annual Report. Operation of the High Flux Reactor. Joint Research Centre, Petten, 1994.
112. Brugger RM, Shih JL, Liu HB: An epithermal neutron beam for neutron capture therapy at the Missouri University Research Reactor. Nucl Technol 98:322-332, 1992.
113. Less TJ, Brugger RM: Reactor moderated intermediate neutron beams for neutron capture therapy. Strahlenther Onkol 165:87-90, 1989.
114. Matsumoto T, Liu HB, Brugger RM: Design of epithermal neutron beams using spent fuel elements at the Mushahi reactor. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp 419-424.
115. Anterinem I, Hiismaki P: Construction of the epithermal BNCT station at the FIPI. In: Abstracts of Sixth International Symposium on Cancer Neutron Capture Therapy. Kobe, Japan. Oct 31-Nov. 4, 1994, p. 64.
116. Su L, Liu Y-WH, Peir J-J, et al: Epithermal neutron beam design for neutron capture therapy at Tsing Hua open-pool reactor. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp 337-342.
117. Liu H-M: Epithermal-neutron beam design for neutron capture therapy at the Tsing-Hua Open Pool Reactor (THOR). In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York. Plenum Press, 1996, pp 385-392.
118. Yamada T, personal communication, 1994.
119. Drewell NH, Lawrence CB, KcKeown J, et al: 600 kW electron-beam power for boron neutron capture therapy with IMPELA. In: Proceedings of the First International Workshop on Accelerator-Based Neutron Sources for Boron Neutron Capture Therapy. Sept. 11-14, 1994, Jackson, Wyoming, edited by D Nigg. US Department of Energy Conference Report CONF-940976, 1994, pp 67-77.
120. Klee KA, Karam RA: Conceptual design for an epithermal neutron beam facility at the Georgia Tech Research Reactor. In: Cancer Neutron Capture Therapy, edited by Y Mishima. New York, Plenum Press, 1996, pp. 357-364.
121. Sweet WH, Soloway AH, Brownell GL: Boron-slow neutron capture therapy of gliomas. Acta Radiologica 1:114-121, 1963.
122. Slatkin DN: A history of boron neutron capture therapy of brain tumors. Brain 114:1696-1629, 1991.
123. Laramore GE, Spence, AM. Boron neutron capture therapy (BNCT) for high grade gliomas of the brain: A cautionary note. Int J Radiat Oncol Biol Phys (in press).
124. Curran Jr. WJ, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993.
125. Takagaki M, Oda Y, Koda Y et al: Effectiveness of borocaptate sodium for boron neutron capture therapy in malignant brain tumors. In: Cancer Neutron Capture Therapy, edited by Y. Mishima. New York, Plenum Press, 1996, pp 571-578.
126. Stragliotto G, Fankhauser H: Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors. Neurosurgery 36:285-293, 1995.
127. 11SH(BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int J Radiat Oncol Biol Phys 28:1175-1181, 1994.
128. 11SH in patients with glioblastoma. Cancer Res 54:6318-6320, 1994.
129. Ceberg CP, Persson A, Brun A, et al: Performance of sulfhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapy. J Neurosurgery 83:79-85, 1995.
130. Watkins P, Harker Y, Amaro C: Nuclear characterization of the HFR Petten BNCT facility. In: Advances in Neutron Capture Therapy, edited by AH Soloway, RF Barth, DE Carpenter. New York, Plenum Press, 1993, pp 59-65.
131. Coderre JA, Glass JD, Fairchild RG, et al: Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res 50:138-141, 1990.
132. Coderre JA, Joel DD, Micca PL, et al: Control of intracerebral gliomsarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat Res 129:290-296, 1992.
133. Saris SC, Solares OR, Wazer DE, et al: Boron neutron capture therapy for murine malignant gliomas. Cancer Res 52:4672-4677, 1992.
134. Matalka KZ, Bailey MQ, Barth RF, et al: Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. Cancer Res 53:3308-3313, 1993.
135. Matalka KZ, Bailey MQ, Barth RF, et al: Boron neutron capture therapy of a rat glioma using boron phenylalanine as a capture agent. Radiat Res 137:44-51, 1994.
136. Barth RF, Matalka KZ, Bailey MQ, et al: A nude rat model for neutron capture therapy of human intracerebral melanoma. Int J Radiat Oncol Biol Phys 28(5):1079-1088, 1994.
137. Coderre JA, Button TM, Micca PL, et al: Neutron capture therapy of the 9L gliosarcoma using the p-boronophenylalanine-fructose complex. Int J Oncol Biol Phys 30:643-652, 1994.
138. Coderre JA, Bergland R, Capala J, et al: Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neuro-oncol 1997 (in press).
139. Zamenhof R, Harling O, Wazer D, et al: Proceedings of an invited review panel to comment on the proposed NEMC/MIT clinical protocol for phase-1 BNCT studies. In: Topics in Dosimetry and Treatment Planning for Neutron Capture Therapy. Madison, WI, Advanced Medical Publishing, 1994, pp 67-79.
140. Nigg DW, Wheeler FJ, Wessol DE, et al: Radiation physics and treatment planning for boron neutron capture therapy of glioblastoma multiforme. J Neuro-oncol 1997 (in press).
141. 10B double resonance. Magn Reson Med 32:170-174, 1994.
142. 11B MRI. Magn Reson Med 34:48-56, 1995.
143. Harling OK, Rogus R, JR Choi: Dosimetry and dose control for clinical trials of neutron capture therapy at the MITR-II reactor. In: Topics in Dosimetry and Treatment Planning for Neutron Capture Therapy. Madison, WI, Advanced Medical Publishing, 1994, pp 67-79.
144. Wheeler FJ, Nigg DW. Three dimensional radiation distribution analysis for boron neutron capture therapy. Nucl Sci Eng 110:16-31, 1992.